# US 2021/0171502 A1 · Methods and composition of 4-substituted benzoylpiperazine-1-substituted carbonyls as beta-catenin/b-cell lymphoma 9 inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0171502 A1
- Document ID: US20210171502A1
- Status: Published application
- Kind: A1
- Application number: 16/087,553
- Filed: 2017-03-24
- Published: 2021-06-10
- Earliest claimed: 2016-03-25
- Assignees: University of Utah Research Foundation
- Applicants: University of Utah Research Foundation
- Inventors: Haitao Ji; Min Zhang
- Web page: https://patentgrep.com/patent/US20210171502A1

## CPC

- C07D 207/12: Oxygen or sulfur atoms
- C07D 403/12: linked by a chain containing hetero atoms as chain links
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 401/14: containing three or more hetero rings
- C07D 403/14: containing three or more hetero rings
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

In one aspect, the invention relates to 4-substituted benzoylpiperazine-1-substituted carbonyls, derivatives thereof, and related compounds; synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating disorders, e.g., various tumors and cancers, associated with β-catenin/BCL9 protein-protein interaction dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

## Claims

### Claim 1

A compound having a structure represented by a formula:
wherein A is —N— or —CR8—;
wherein R8 is hydrogen, halogen, C1-C3 alkyl, C1-C3 monohaloalkyl, or C1-C3 polyhaloalkyl;
wherein L1 is optionally present, and when present, is O, S, or NH;
wherein L2 is optionally present, and when present, is O, S, NR9, or —(CR10aR10b)n—;
wherein n is an integer having the value of 1, 2, or 3;
wherein R9 is hydrogen, C1-C3 alkyl, C1-C3 monohaloalkyl, or C1-C3 polyhaloalkyl;
wherein each occurrence of R10a and R10a is independently hydrogen, C1-C3 alkyl, C1-C3 monohaloalkyl, or C1-C3 polyhaloalkyl;
wherein each of R1a and R1b is independently hydrogen, halogen, C1-C3 alkyl, C1-C3 monohaloalkyl, or C1-C3 polyhaloalkyl;
wherein each of R2a, R2b, and R2c is independently hydrogen, halogen, C1-C3 alkyl, C1-C3 haloalkyl, or C1-C3 polyhaloalkyl;
wherein R3 is Cy3 or Ar1;
wherein Cy3 is a C3-C8 cycloalkyl or a C2-C7 heterocycloalkyl; and wherein Cy3 is substituted 0, 1, 2, or 3 groups independently selected from halogen, —CN, C1-C3 alkyl, C1-C3 monohaloalkyl, C1-C3 polyhaloalkyl, cyclopropyl, and —CO2H;
wherein Ar1 is selected from aryl and heteroaryl, and wherein Ar1 is substituted with 0, 1, 2, or 3 groups independently selected from halogen, —CN, C1-C3 alkyl, C1-C3 monohaloalkyl, C1-C3 polyhaloalkyl, cyclopropyl, and —CO2H;
wherein R4 is hydrogen, halogen, C1-C3 alkyl, C1-C3 haloalkyl, or C1-C3 polyhaloalkyl;
wherein each occurrence of R5 is independently selected from hydrogen, C1-C8 alkyl, C1-C8 monohaloalkyl, or C1-C8 polyhaloalkyl;
wherein R6 is C1-C6 aminoalkyl, C1-C6 hydroxyalkyl, or Cy1; and wherein Cy1 is an amino C3-C8 cycloalkyl, a hydroxy C3-C8 cycloalkyl, or a C2-C7 heterocycloalkyl comprising at least one oxygen or nitrogen atom; and wherein Cy1 is substituted 0, 1, 2, or 3 groups independently selected from halogen, C1-C4 alkyl, C1-C4 monohaloalkyl, and C1-C4 polyhaloalkyl;
wherein R7 is H2N—(C1-C6 alkyl)-(C═O)—; HO—(C1-C6 alkyl)—(C═O)—; C1-C6 aminoalkyl, C1-C6 hydroxyalkyl, or Cy2; and wherein Cy2 is an amino C3-C8 cycloalkyl, a hydroxy C3-C8 cycloalkyl, or a C2-C7 heterocycloalkyl comprising at least one oxygen or nitrogen atom; and wherein Cy2 is substituted 0, 1, 2, or 3 groups independently selected from halogen, C1-C4 alkyl, C1-C4 monohaloalkyl, and C1-C4 polyhaloalkyl;
or a pharmaceutically acceptable salt thereof

### Claim 2 (depends on 1)

The compound of claim 1, wherein L2 is not present.

### Claim 3 (depends on 1)

The compound of claim 1, wherein Cy2 has a structure represented by a formula:
and wherein R10 is hydrogen, methyl, ethyl, propyl, or isopropyl.

### Claim 4 (depends on 1)

The compound of claim 1, wherein each of R1a, R1b, R2a, R2b, and R2c is hydrogen.

### Claim 5 (depends on 1)

The compound of claim 1, wherein R3 is phenyl substituted 0, 1, 2, or 3 groups independently selected from halogen, —CN, C1-C3 alkyl, C1-C3 monohaloalkyl, C1-C3 polyhaloalkyl, cyclopropyl, and —CO2H.

### Claim 6 (depends on 1)

The compound of claim 1, wherein R3 is cyclohexyl substituted 0, 1, 2, or 3 groups independently selected from halogen, —CN, C1-C3 alkyl, C1-C3 monohaloalkyl, C1-C3 polyhaloalkyl, cyclopropyl, and —CO2H.

### Claim 7 (depends on 1)

The compound of claim 1, having a structure represented by a formula:
wherein R3 is cyclohexyl or phenyl substituted 0, 1, 2, or 3 groups independently selected from halogen, —CN, C1-C3 alkyl, C1-C3 monohaloalkyl, C1-C3 polyhaloalkyl, cyclopropyl, and —CO2H; wherein R4 is —F, —Cl —Br, methyl, ethyl, —CFH2, —CF2H, or —CF3; wherein R10 is hydrogen, methyl, ethyl, propyl, or isopropyl; and wherein R11 is hydrogen, methyl, ethyl, propyl, or isopropyl.

### Claim 8 (depends on 1)

The compound of claim 1, present as:
or a subgroup thereof.

### Claim 9 (depends on 1)

A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

### Claim 10

A method for the treatment of a disorder of uncontrolled cellular proliferation associated with a β-catenin/BCL9 dysfunction in a mammal comprising the step of administering to the mammal an effective amount of at least one compound having a structure represented by a formula:
wherein A is —N— or —CR8—;
wherein R8 is hydrogen, halogen, C1-C3 alkyl, C1-C3 monohaloalkyl, or C1-C3 polyhaloalkyl;
wherein L1 is optionally present, and when present, is O, S, or NH;
wherein L2 is optionally present, and when present, is O, S, NR9, or —(CR10aR10b)n—;
wherein n is an integer having the value of 1, 2, or 3;
wherein R9 is hydrogen, C1-C3 alkyl, C1-C3 monohaloalkyl, or C1-C3 polyhaloalkyl;
wherein each occurrence of R10a and R10a is independently hydrogen, C1-C3 alkyl, C1-C3 monohaloalkyl, or C1-C3 polyhaloalkyl;
wherein each of R1a and R1b is independently hydrogen, halogen, C1-C3 alkyl, C1-C3 monohaloalkyl, or C1-C3 polyhaloalkyl;
wherein each of R2a, R2b, and R2c is independently hydrogen, halogen, C1-C3 alkyl, C1-C3 haloalkyl, or C1-C3 polyhaloalkyl;
wherein R3 is Cy3 or Ar1;
wherein Cy3 is a C3-C8 cycloalkyl or a C2-C7 heterocycloalkyl; and wherein Cy3 is substituted 0, 1, 2, or 3 groups independently selected from halogen, —CN, C1-C3 alkyl, C1-C3 monohaloalkyl, C1-C3 polyhaloalkyl, cyclopropyl, and —CO2H;
wherein Ar1 is selected from aryl and heteroaryl, and wherein Ar1 is substituted with 0, 1, 2, or 3 groups independently selected from halogen, —CN, C1-C3 alkyl, C1-C3 monohaloalkyl, C1-C3 polyhaloalkyl, cyclopropyl, and —CO2H;
wherein R4 is hydrogen, halogen, C1-C3 alkyl, C1-C3 haloalkyl, or C1-C3 polyhaloalkyl;
wherein each occurrence of R5 is independently selected from hydrogen, C1-C8 alkyl, C1-C8 monohaloalkyl, or C1-C8 polyhaloalkyl;
wherein R6 is C1-C6 aminoalkyl, C1-C6 hydroxyalkyl, or Cy1; and wherein Cy1 is an amino C3-C8 cycloalkyl, a hydroxy C3-C8 cycloalkyl, or a C2-C7 heterocycloalkyl comprising at least one oxygen or nitrogen atom; and wherein Cy1 is substituted 0, 1, 2, or 3 groups independently selected from halogen, C1-C4 alkyl, C1-C4 monohaloalkyl, and C1-C4 polyhaloalkyl;
wherein R7 is H2N—(C1-C6 alkyl)-(C═O)—; HO—(C1-C6 alkyl)-(C═O)—; C1-C6 aminoalkyl, C1-C6 hydroxyalkyl, or Cy2; and wherein Cy2 is an amino C3-C8 cycloalkyl, a hydroxy C3-C8 cycloalkyl, or a C2-C7 heterocycloalkyl comprising at least one oxygen or nitrogen atom; and wherein Cy2 is substituted 0, 1, 2, or 3 groups independently selected from halogen, C1-C4 alkyl, C1-C4 monohaloalkyl, and C1-C4 polyhaloalkyl;
or a pharmaceutically acceptable salt thereof.

### Claim 11 (depends on 10)

The method of claim 10, wherein the mammal has been diagnosed with a need for treatment of the disorder prior to the administering step.

### Claim 12 (depends on 11)

The method of claim 11, wherein the mammal is human; and wherein the human has been identified to have a 1q21 chromosomal abnormality.

### Claim 13 (depends on 10)

The method of claim 10, further comprising the step of identifying a mammal in need of treatment of the disorder.

### Claim 14 (depends on 13)

The method of claim 13, wherein the mammal is human; and wherein the step of identifying the human in need of treatment of the disorder comprises the steps of:
(a) obtaining a sample from the human, wherein the sample comprises cells suspected of being associated with the disorder of uncontrolled cellular proliferaton;
(b) determining if the sample comprises cells with a 1q21 chromosomal abnormality; and
(c) administering to the human the compound when the sample is positive for a 1q21 chromosomal abnormality.

### Claim 15 (depends on 10)

The method of claim 10, wherein the disorder is cancer.

### Claim 16 (depends on 15)

The method of claim 15, wherein the cancer is selected from breast cancer, cervical cancer, gastrointestinal cancer, colorectal cancer, brain cancer, skin cancer, prostate cancer, ovarian cancer, thyroid cancer, testicular cancer, pancreatic cancer, endometrial cancer, melanoma, glioma, leukemia, lymphoma, chronic myeloproliferative disorder, myelodysplastic syndrome, myeloproliferative neoplasm, and plasma cell neoplasm (myeloma).

### Claim 17

A method for inhibiting protein-protein interactions of β-catenin and BCL9 in at least one cell, comprising the step of contacting the at least one cell with an effective amount of at least one compound having a structure represented by a formula:
wherein A is —N— or —CR8—;
wherein R8 is hydrogen, halogen, C1-C3 alkyl, C1-C3 monohaloalkyl, or C1-C3 polyhaloalkyl;
wherein L1 is optionally present, and when present, is O, S, or NH;
wherein L2 is optionally present, and when present, is O, S, NR9, or —(CR10aR10b)n—;
wherein n is an integer having the value of 1, 2, or 3;
wherein R9 is hydrogen, C1-C3 alkyl, C1-C3 monohaloalkyl, or C1-C3 polyhaloalkyl;
wherein each occurrence of R10a and R10a is independently hydrogen, C1-C3 alkyl, C1-C3 monohaloalkyl, or C1-C3 polyhaloalkyl;
wherein each of R1a and R1b is independently hydrogen, halogen, C1-C3 alkyl, C1-C3 monohaloalkyl, or C1-C3 polyhaloalkyl;
wherein each of R2a, R2b, and R2c is independently hydrogen, halogen, C1-C3 alkyl, C1-C3 haloalkyl, or C1-C3 polyhaloalkyl;
wherein R3 is Cy3 or Ar1;
wherein Cy3 is a C3-C8 cycloalkyl or a C2-C7 heterocycloalkyl; and wherein Cy3 is substituted 0, 1, 2, or 3 groups independently selected from halogen, —CN, C1-C3 alkyl, C1-C3 monohaloalkyl, C1-C3 polyhaloalkyl, cyclopropyl, and —CO2H;
wherein Ar1 is selected from aryl and heteroaryl, and wherein Ar1 is substituted with 0, 1, 2, or 3 groups independently selected from halogen, —CN, C1-C3 alkyl, C1-C3 monohaloalkyl, C1-C3 polyhaloalkyl, cyclopropyl, and —CO2H;
wherein R4 is hydrogen, halogen, C1-C3 alkyl, C1-C3 haloalkyl, or C1-C3 polyhaloalkyl;
wherein each occurrence of R5 is independently selected from hydrogen, C1-C8 alkyl, C1-C8 monohaloalkyl, or C1-C8 polyhaloalkyl;
wherein R6 is C1-C6 aminoalkyl, C1-C6 hydroxyalkyl, or Cy1; and wherein Cy1 is an amino C3-C8 cycloalkyl, a hydroxy C3-C8 cycloalkyl, or a C2-C7 heterocycloalkyl comprising at least one oxygen or nitrogen atom; and wherein Cy1 is substituted 0, 1, 2, or 3 groups independently selected from halogen, C1-C4 alkyl, C1-C4 monohaloalkyl, and C1-C4 polyhaloalkyl;
wherein R7 is H2N—(C1-C6 alkyl)-(C═O)—; HO—(C1-C6 alkyl)-(C═O)—; C1-C6 aminoalkyl, C1-C6 hydroxyalkyl, or Cy2; and wherein Cy2 is an amino C3-C8 cycloalkyl, a hydroxy C3-C8 cycloalkyl, or a C2-C7 heterocycloalkyl comprising at least one oxygen or nitrogen atom; and wherein Cy2 is substituted 0, 1, 2, or 3 groups independently selected from halogen, C1-C4 alkyl, C1-C4 monohaloalkyl, and C1-C4 polyhaloalkyl, or a pharmaceutically acceptable salt thereof

### Claim 18 (depends on 17)

The method of claim 17, wherein the cell is human.

### Claim 19 (depends on 17)

The method of claim 17, wherein the cell has been isolated from a mammal prior to the contacting step.

### Claim 20 (depends on 17)

The method of claim 17, wherein contacting is via administration to a mammal.
